EU Issues Study on REACH Implementation

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) reported in late July that Eurostat, the Statistical Office of the European Communities, recently published a baseline study or the first snapshot of REACH policy in the preregistration phase.

The Society of Chemical Manufacturers and Affiliates (SOCMA) reported in late July that Eurostat, the Statistical Office of the European Communities, recently published a baseline study or the first snapshot of REACH policy in the preregistration phase. SOCMA is the US-based trade association representing custom and batch manufacturers, including contract manufacturers of pharmaceutical intermediates and active pharmaceutical ingredients.

REACH is the European Union (EU) regulation governing the registration, evaluation, authorization, and restriction of chemicals. The regulation was put into place to require registration of approximately 30,000 substances produced or imported within the EU. Substance registration is prioritized according to the phase-in timeline based on the volume and hazardous characteristics of the materials.

The Eurostat study, The REACH Baseline Study: A Tool to Monitor the New EU Policy on Chemicals-REACH, lays out a foundation for future studies using a set of indicators, in order to monitor the success of REACH, according to a SOCMA press release. The three main indicators most closely related to the main objectives of REACH were noted as administrative indicators, a risk and quality indicator system, and supplementary indicators.

The study will monitor changes to risk and the current information base on chemicals, including the quality of such information. The study noted the difficulty in tracking risk reduction and used a subset of chemicals taken out of the approximately 30,000 chemicals regulated under REACH.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes